SCHEMBL4483973

SCHEMBL4483973

O=Cc1cccc2ccc(OCc3ccccc3)cc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.59
MAOA P21397 2/20 0.56
MAOB P27338 2/20 0.56
RAB9A P51151 4/20 0.52
NPC1 O15118 4/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
MAPT P10636 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
PLAU P00749 1/20 0.50
PLAT P00750 1/20 0.50
CYP3A4 P08684 1/20 0.50
MRGPRX4 Q96LA9 1/20 0.50
PTGER3 P43115 1/20 0.48
PTGDR Q13258 1/20 0.48
IP6K1 Q92551 1/20 0.48
CCNB2 O95067 1/20 0.48
CDK1 P06493 1/20 0.48
CDK4 P11802 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19660281 0.81 MAOA (0.51) ALOX5MAOAMAOBRAB9ANPC1
SCHEMBL21822328 0.79 LMNA (0.50) MAOBRAB9ANPC1L3MBTL1KMT2A
SCHEMBL10606515 0.79 ALOX5 (0.67) ALOX5MAOAMAOBRAB9ANPC1
SCHEMBL3399608 0.79 IP6K1 (0.56) ALOX5MAOAMAOBRAB9ANPC1
SCHEMBL13523860 0.79 MAOB (0.51) ALOX5MAOAMAOBRAB9ANPC1
SCHEMBL8327914 0.79 MAOA (0.61) ALOX5MAOAMAOBRAB9ANPC1
SCHEMBL4079350 0.78 ALOX5 (0.65) ALOX5MAOAMAOBRAB9ANPC1
SCHEMBL22703560 0.78 ALOX5 (0.65) ALOX5MAOAMAOBNPC1MEN1
SCHEMBL38662923 0.78 ALOX5 (0.65) ALOX5MAOAMAOBNPC1MEN1
SCHEMBL4477944 0.78 ALOX5 (0.65) ALOX5MAOAMAOBNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258910-A1 benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; IRM LLC (BM) 2009-10-15 US disclosed
US-7569593-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-08-04 US disclosed
CN-100455579-C Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-01-28 CN disclosed
EP-1670780-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-12-17 EP disclosed
CN-1860111-A Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2006-11-08 CN disclosed
EP-1670780-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-06-21 EP disclosed
US-20050209285-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-09-22 US disclosed
WO-2005030151-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258910-A1 benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; PDGFRA, RAF1, FLT1 ALOX5 3539/4885MAOA 3530/4885MAOB 3682/4885
US-20050209285-A1 Compounds and compositions as protein kinase inhibitors LCK, RAF1, MAP3K1 ALOX5 4262/4885MAOA 3164/4885MAOB 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.